The Cell Therapy Network (TerCel) is a collaborative project that began its activity under the first call RETICS of Carlos III Health Institute in 2003. It's target is to promote research in cell therapy and transfer scientific advances in this field to the patients of the National Health System.
The TerCel network is made up of 32 groups from all over Spain that include 382 basic researchers, clinicians and medical professionals working together, under a multidisciplinary and cooperative approach, with the main objective of discovering and describing the mechanisms of the beneficial actions of the cell therapy in human diseases through the development of experimental approaches, including transplantation of autologous and heterologous cells from different cell populations (adult, embryonic or IPSC), to improve the health of patients.
This Cell Therapy Network has the main objective of contributing to the treatment of human diseases through the use of cell therapy and other advanced therapies. To achieve this purpose, the collaborative work of the network components has been distributed in three work programs, with their corresponding specific objectives in basic science, preclinical and clinical trials. These lines of action develop a common strategic research plan that is described as "from the bench to the bedside and return" and that constitutes the basic cycle of research in the TerCel Network.
iCor researchers participate in the ##CardioCel line:
Cardiocel line consists in research, development, production and application of cell therapy in cardiovascular diseases. Objectives in basic research: Know the mechanisms of cardiac regeneration and remodeling and the role of stem cells.
Objectives in preclinical research: Develop cellular and tissue engineering strategies for cardiac repair and regeneration. Objectives in translational research: Implementation of platforms and clinical trials that allow the application of advances in cardiac regeneration.